STANFORD UNIVERSITY SCHOOL OF MEDICINE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1908-01-01
- Employees
- 5K
- Market Cap
- -
LumiThera's Valeda Light Delivery System Shows Extended Vision Benefits in Dry AMD Patients Over 4.5 Years
• LumiThera's Valeda Light Delivery System, FDA-authorized in November 2024, demonstrated sustained vision improvement of over one line on the eye chart in more than 60% of dry AMD patients through 4.5 years of follow-up.
• The LIGHTSITE IIIB extension trial results showed that patients maintained some vision benefits during a 20-month treatment gap and recovered vision upon retreatment, suggesting the therapy may modify disease trajectory.
• As the first non-invasive treatment authorized to improve vision in dry AMD, Valeda uses photobiomodulation to enhance mitochondrial function at the cellular level, offering a treatment option before permanent vision loss occurs.
Signatera ctDNA Test Predicts Recurrence Risk in High-Risk Breast Cancer Patients, I-SPY 2 Trial Data Shows
• Natera's Signatera test demonstrated that patients with detectable circulating tumor DNA at diagnosis had three times higher risk of recurrence in early-stage, high-risk breast cancer, according to I-SPY 2 trial data to be presented at ESMO Breast Annual Congress.
• The study of 712 patients revealed that pre-treatment ctDNA quantity significantly correlates with clinical outcomes in breast cancer, with Signatera status emerging as the most significant predictor of distant recurrence-free survival regardless of disease subtype.
• Researchers suggest these findings could lead to new treatment protocols, potentially allowing Signatera-negative patients to avoid chemotherapy or other intensive treatments, representing a significant advancement in personalized breast cancer care.
Guardant Health's Shield Multi-Cancer Detection Test Shows Strong Performance Across 10 Cancer Types
• Guardant Health's blood-based Shield Multi-Cancer Detection test demonstrated 98.5% specificity and 60% overall sensitivity across ten tumor types, with particularly strong results for aggressive cancers.
• The test achieved 89% accuracy for cancer signal of origin prediction, potentially enabling clinicians to identify the primary tumor location through a simple blood draw.
• Based on these promising results, the National Cancer Institute selected Shield MCD for its upcoming Vanguard Study evaluating emerging multi-cancer detection technologies.
AI Tool Successfully Predicts Prostate Cancer Treatment Outcomes by Measuring Tumor Volume
• A new AI system accurately identified and outlined 85% of aggressive prostate tumors on MRI scans, helping physicians predict cancer spread better than traditional risk calculations.
• Researchers found that AI-measured tumor volume strongly correlates with treatment success, with tumors larger than 1.5cc significantly more likely to resist treatment and metastasize.
• The technology could advance precision medicine for prostate cancer patients by enabling earlier treatment decisions and more targeted radiation therapy approaches.
Oncology Workforce Crisis Drives Push for Enhanced Collaboration and Value-Based Care
• Experts project a 40% increase in cancer care demand amid growing oncologist shortages, emphasizing the critical need for streamlined collaboration between healthcare providers and payers.
• Fred Hutchinson Cancer Center demonstrates success with multidisciplinary care model, expanding from 3 to 13 team members and implementing innovative outpatient-specific approaches to improve patient care delivery.
• Healthcare leaders stress the importance of balancing clinical guidelines with personalized care while highlighting the potential of emerging treatments like TIL therapy in addressing complex cancer cases.
HealthBio Launches FDA Fast-Track Trial for Long COVID Treatment Using Maraviroc-Atorvastatin Combination
• HealthBio initiates Phase III clinical trial testing a novel combination of Selzentry (maraviroc) and Lipitor (atorvastatin) for Long COVID treatment, involving 252 patients in a randomized, double-blind study.
• The company's approach targets vascular inflammation through CCR5 pathway modulation, supported by preliminary data showing promising results in over 12,000 treated patients.
• With $10M initial funding and FDA Fast-Track designation, the trial aims to address a condition affecting up to 23 million Americans and causing an estimated $3.7 trillion economic impact.
VA Study Reveals 11% of Primary Care Appointments Face Same-Day Cancellations
• A comprehensive analysis of over 114 million VA healthcare appointments shows 10.87% were canceled on the same day, with patient cancellations, no-shows, and clinic cancellations being the primary reasons.
• During the initial COVID-19 wave, same-day cancellations of in-person appointments increased by 13.5% compared to 2019, primarily driven by clinic-initiated cancellations.
• Despite the high cancellation rate, the VA system demonstrates similar or lower levels of unused appointments compared to other healthcare providers, while maintaining stable rates from 2018 to 2024.
Medtronic's BrainSense Adaptive DBS Receives CE Mark for Personalized Parkinson's Therapy
• Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) and Electrode Identifier (EI) have received CE Mark approval in the EU and UK.
• The aDBS system offers real-time, self-adjusting brain stimulation for Parkinson's disease, adapting to individual patient's unique brain activity.
• BrainSense Electrode Identifier improves DBS programming by facilitating optimal initial contact selection, reducing programming time for clinicians.
• The first European patient has already been programmed with the new system at Amsterdam University Medical Center, marking a significant advancement.
Rapport Therapeutics' RAP-219 Shows Promise in Phase 1 Trials for CNS Disorders
• Rapport Therapeutics' RAP-219 achieved target receptor occupancy within five days, supporting its potential for treating CNS disorders.
• The Phase 1 trials demonstrated a favorable tolerability profile for RAP-219, with no serious adverse events reported in healthy volunteers.
• RAP-219 selectively targets TARPγ8-associated AMPA receptors, potentially enhancing the therapeutic index for AMPA receptor modulation.
• A Phase 2a trial of RAP-219 in focal epilepsy is ongoing, with topline data expected in mid-2025, according to Rapport Therapeutics.
Debate Over CAR-T Therapy's Secondary Malignancy Risks Continues
The FDA's 2024 mandate for boxed warnings on CAR-T cell therapies due to potential risks of secondary T-cell malignancies has sparked debate among clinicians and researchers. While initial concerns were raised, subsequent studies suggest the risk is low and comparable to other treatments, questioning the necessity of the warning.
Acelyrin's Lonigutamab Shows Promise in Phase 2 Data for Thyroid Eye Disease
• Acelyrin's lonigutamab demonstrates a potential best-in-class efficacy and safety profile for treating Thyroid Eye Disease (TED), according to updated Phase 2 data.
• A virtual investor event on January 6, 2025, will feature clinician perspectives on unmet needs in TED and the design of the Phase 3 LONGITUDE program.
• The Phase 3 LONGITUDE program, developed after discussions with the FDA, aims to be the most inclusive registrational program in TED to date.
• Lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, offers potential for longer-term, convenient dosing, improving clinical response.
Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease Phase 2 Data
• Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED).
• The company plans to unveil the design for its Phase 3 program following a successful meeting with the FDA.
• A virtual investor event is scheduled to reveal the data and Phase 3 design, featuring experts from Stanford and the University of Colorado School of Medicine.
CGM and Machine Learning Identify Metabolic Subphenotypes in Type 2 Diabetes
• A recent study leverages continuous glucose monitoring (CGM) and machine learning to identify distinct metabolic subphenotypes within type 2 diabetes.
• The research utilizes data from oral glucose tolerance tests (OGTT) and insulin suppression tests to classify individuals based on insulin resistance, beta-cell function, and incretin effect.
• Machine learning models trained on OGTT glucose time series data demonstrate high accuracy in predicting metabolic subphenotypes, offering a potential tool for personalized diabetes management.
• The study highlights the potential of CGM and advanced analytics to refine our understanding of diabetes heterogeneity and tailor treatment strategies.
Study Reveals Significant Sleep Disruption Among Parents of Children with Atopic Dermatitis
• National Health Interview Survey analysis shows 45.2% of parents with children having atopic dermatitis fail to get recommended 7 hours of sleep, compared to 37.1% of other parents.
• Parents of children with eczema are 26% more likely to use sleep medications, with 13.3% reporting sleep aid use versus 9.9% in the control group.
• The study, analyzing data from 2013-2018, represents over 6.1 million U.S. parents, highlighting the significant indirect health impact of pediatric atopic dermatitis on caregivers.
Real-World Data Reinforces Cilta-Cel Efficacy in Relapsed Multiple Myeloma, While Ide-Cel Shows Promise in CNS Involvement
• Real-world evidence confirms cilta-cel's effectiveness in relapsed/refractory multiple myeloma, mirroring clinical trial outcomes with high response rates and durable remission.
• A significant portion of patients in the real-world study wouldn't have met clinical trial eligibility, highlighting cilta-cel's potential in a broader patient population.
• Ide-cel demonstrates promising results in patients with CNS involvement of multiple myeloma, showing favorable responses and manageable safety profiles in a retrospective analysis.
• Renal impairment does not significantly impact the efficacy of BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma, though increased monitoring for ICANS and infections may be warranted.
Acelyrin's Lonigutamab Shows Promise in Phase 2, Phase 3 Program Design Announced for Thyroid Eye Disease
• Acelyrin's lonigutamab demonstrated clinically meaningful improvements in Thyroid Eye Disease (TED) symptoms, including proptosis, CAS, and diplopia, in Phase 2 trials.
• The Phase 3 LONGITUDE program, consisting of two global trials, is set to begin in Q1 2025, evaluating lonigutamab's safety and efficacy with topline data expected in H2 2026.
• Lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody, showed a favorable safety profile with no reported cases of hearing impairment, hyperglycemia, or menstrual disorders.
• Acelyrin's strategic focus shifts to lonigutamab after izokibep fails in Phase 2b/3 uveitis trial, with existing cash resources projected to last through mid-2027.
Scilex Bio's KDS2010 Shows Promise in Phase 2 Trials for Obesity and Alzheimer's
• Scilex Bio's KDS2010, a reversible MAO-B inhibitor, is in Phase 2 trials for obesity, with U.S. patient enrollment planned for 2025, targeting metabolism without affecting appetite.
• Phase 2 trials for KDS2010 in Alzheimer's are underway, enrolling 114 patients in South Korea, with plans to expand to the U.S. in 2025.
• KDS2010 uniquely targets astrocytic GABA inhibition, potentially improving cognitive function in Alzheimer's and offering advantages over existing GLP-1 obesity treatments.
• Phase 1 trials demonstrated KDS2010's favorable safety, tolerability, and pharmacokinetics for once-daily dosing, positioning it for further development in both disease areas.
IO-202 Plus Azacitidine Shows Promise in Treating CMML
• IO-202 combined with azacitidine achieved a 50% complete remission rate and a 66.7% overall response rate in CMML patients naive to hypomethylating agents.
• Notably, patients with high LILRB4 expression showed an 83.3% complete remission rate and a 100% overall response rate with the combination therapy.
• The combination enabled nearly 40% of patients to successfully undergo hematopoietic stem cell transplant, a potentially curative option.
• IO-202 was well-tolerated, with no dose-limiting toxicities reported, suggesting a favorable safety profile in combination with azacitidine.
Lungpacer's AeroPace System Receives FDA Approval for Ventilator Weaning
• The FDA has granted premarket approval to Lungpacer Medical's AeroPace System, a neurostimulation therapy designed to improve weaning outcomes for adults on mechanical ventilation.
• AeroPace stimulates the phrenic nerves to strengthen the diaphragm, leading to improved breathing and reduced dependence on mechanical ventilation for patients ventilated for at least 96 hours.
• Clinical trials demonstrated that AeroPace increased weaning success, reduced ventilator days by nearly three days, and decreased the risk of reintubation by up to 60%.
• The AeroPace System represents a significant advancement in respiratory care, offering a new treatment option for critical care patients struggling to wean from mechanical ventilation.
VA Expands Cancer Care Access Through Innovative Programs and Telehealth Services
• Veterans Affairs is addressing cancer care barriers through multiple initiatives including telehealth services, community-based infusion centers, and educational programs to improve patient outcomes.
• The VA's Close to Me Novel Infusion Care Delivery service has reduced patient travel by over 200,000 miles across 22 new sites, achieving a 99% treatment adherence rate.
• Veterans with cancer face unique challenges including higher rates of lung, prostate, and bladder cancers, with studies showing better outcomes when care is received within VA settings versus non-VA facilities.
© Copyright 2025. All Rights Reserved by MedPath